(Q42260262)

English

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

scientific article published on 23 October 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

0 references

author name string

Xiao Tong

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sophie Le Pogam

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Lewyn Li

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Kristin Haines

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Katherine Piso

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Victoria Baronas

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jun-Mei Yan

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sung-Sau So

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Klaus Klumpp

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Isabel Nájera

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

23 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

209

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

668-675

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

The HCV NS5B nucleoside and non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

New NS5B polymerase inhibitors for hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Identifiers

10.1093/INFDIS/JIT562

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42260262&oldid=1940375021"